Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 22:12:1039366.
doi: 10.3389/fonc.2022.1039366. eCollection 2022.

LINC00324 in cancer: Regulatory and therapeutic implications

Qing Xia  1   2   3 , Jinze Shen  1 , Qurui Wang  1 , Yufei Ke  1 , Qibin Yan  1 , Hanbing Li  2 , Dayong Zhang  1 , Shiwei Duan  1
Affiliations
Review

LINC00324 in cancer: Regulatory and therapeutic implications

Qing Xia et al. Front Oncol. .

Abstract

LINC00324 is a 2082 bp intergenic noncoding RNA. Aberrant expression of LINC00324 was associated with the risk of 11 tumors and was closely associated with clinicopathological features and prognostic levels of 7 tumors. LINC00324 can sponge multiple miRNAs to form complex ceRNA networks, and can also recruit transcription factors and bind RNA-binding protein HuR, thereby regulating the expression of a number of downstream protein-coding genes. LINC00324 is involved in 4 signaling pathways, including the PI3K/AKT signaling pathway, cell cycle regulatory pathway, Notch signaling pathway, and Jak/STAT3 signaling pathway. High expression of LINC00324 was associated with larger tumors, a higher degree of metastasis, a higher TNM stage and clinical stage, and shorter OS. Currently, four downstream genes in the LINC00324 network have targeted drugs. In this review, we summarize the molecular mechanisms and clinical value of LINC00324 in tumors and discuss future directions and challenges for LINC00324 research.

Keywords: LINC00324; RNA-Binding Protein; cancer; ceRNA; prognosis; signaling pathway.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The mechanisms of LINC00324 in cancer. BC, Breast cancer; HCC, Hepatocellular carcinoma; NSCLC, Non-small cell lung carcinoma; SaOS, Osteosarcoma.
Figure 2
Figure 2
Effect of LINC00324 on cancer development. Red represents the mechanism of promoting cancer, and blue represents the mechanism of inhibiting cancer. BC, Breast cancer; CRC, Colorectal cancer; GC, Gastric cancer; HCC, Hepatocellular carcinoma; IOT, Immature ovarian teratocarcinoma; LAC, Lung adenocarcinoma; NPC, Nasopharyngeal carcinoma; NSCLC, Non-small cell lung carcinoma; PTC, Papillary thyroid cancer; RB, Retinoblastoma; SaOS, Osteosarcoma. (created by BioRender).
Figure 3
Figure 3
The competing endogenous RNA (ceRNA) mechanism and potential downstream regulatory mechanisms of LINC00324. BC, Breast cancer; CRC, Colorectal cancer; GC, Gastric cancer; IOT, Immature ovarian teratocarcinoma; LAC, Lung adenocarcinoma; NPC, Nasopharyngeal carcinoma; NSCLC, Non-small cell lung carcinoma; PTC, Papillary thyroid cancer; RB, Retinoblastoma.
Figure 4
Figure 4
The role of LINC00324 in signaling pathways. IOT, Immature ovarian teratocarcinoma; NPC, Nasopharyngeal carcinoma; PTC, Papillary thyroid cancer; RB, Retinoblastoma.
Figure 5
Figure 5
Therapeutic drugs related to target genes.
Figure 6
Figure 6
LINC00324 regulates cancer phenotype through ceRNA axes. BC, Breast cancer; CRC, Colorectal cancer; GC, Gastric cancer; LAC, Lung adenocarcinoma; NPC, Nasopharyngeal carcinoma; NSCLC, Non-small cell lung carcinoma; PTC, Papillary thyroid cancer; RB, Retinoblastoma.
See this image and copyright information in PMC

References

    1. Chan JJ, Tay Y. Noncoding RNA:RNA regulatory networks in cancer. Int J Mol Sci (2018) 19(5):1310. doi: 10.3390/ijms19051310 - DOI - PMC - PubMed
    1. Shen J, Wu Y, Ruan W, Zhu F, Duan S. miR-1908 dysregulation in human cancers. Front Oncol (2022) 12:857743. doi: 10.3389/fonc.2022.857743 - DOI - PMC - PubMed
    1. Zhang Q, Zhong C, Shen J, Chen S, Jia Y, Duan S. Emerging role of LINC00461 in cancer. BioMed Pharmacother (2022) 152:113239. doi: 10.1016/j.biopha.2022.113239 - DOI - PubMed
    1. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell (2011) 43(6):904–14. doi: 10.1016/j.molcel.2011.08.018 - DOI - PMC - PubMed
    1. Lau E. Non-coding RNA: Zooming in on lncRNA functions. Nat Rev Genet (2014) 15(9):574–5. doi: 10.1038/nrg3795 - DOI - PubMed